SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced a successful outcome from the Company’s Type A meeting with the U.S. Food and Drug Administration (FDA) in which alignment was reached on the Company’s plan to submit additional estimated glomerular filtration rate (eGFR) data from the ongoing pivotal Phase 3 DUPLEX Study of sparsentan in focal segmental glomerulosclerosis (FSGS) to support an application for accelerated approval in 2022.

Read the full press release >

July 26, 2021 -- Today, Rare Revolution Magazine launched its summer issue dedicated to diversity, equity and inclusion in rare disease. The issue explores ways that rare disease patient advocacy organizations, individuals and industry are working to advance health equity. Articles include conversations with members of the rare community about race, gender, sexual identity, age bias, access to clinical trials and therapy. Travere is proud to collaborate with Rare Revolution Magazine on this issue. Read the issue >

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder that often progresses to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in August 2021.

Read the full press release >